Europe Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030
The Europe lung cancer diagnostics market is projected to register a substantial CAGR of 13.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Market Segmentation
Europe Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Europe lung cancer diagnostics market are:
• Rise in market players and the availability of advanced services
• Increase in awareness about the lung cancer diagnostics
Market Players
Some of the major players operating in the Europe lung cancer diagnostics market are:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott
• Quest Diagnostics Incorporated
• Bio-Rad Laboratories, Inc.
• Biocartis
• Danaher
• DiaSorin S.p.A.
• Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)
• Inivata Ltd.
• Myriad Genetics, Inc.
• NeoGenomics Laboratories
• PerkinElmer Inc.
• Vela Diagnostics
• QIAGEN
• Siemens Healthcare GmbH
• Veracyte, Inc.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook